Provided by Tiger Fintech (Singapore) Pte. Ltd.

Fate Therapeutics

0.9415
-0.0020-0.21%
Post-market: 0.94480.0033+0.35%19:49 EDT
Volume:1.42M
Turnover:1.33M
Market Cap:107.89M
PE:-0.57
High:0.9695
Open:0.9695
Low:0.9102
Close:0.9435
Loading ...

Fate Therapeutics (FATE) Up 0.5% Since Last Earnings Report: Can It Continue?

Zacks
·
13 Dec 2024

Barclays Gives a Buy Rating to Fate Therapeutics (FATE)

TIPRANKS
·
11 Dec 2024

Hold Rating for Fate Therapeutics Amid Incremental Progress in CD19 CAR-T Therapy Development

TIPRANKS
·
10 Dec 2024

Fate Therapeutics Reports FT819 Shows 'Favorable Safety Profile,' Clinical Benefits

MT Newswires Live
·
10 Dec 2024

BRIEF-Fate Therapeutics Presents New Phase 1 Clinical Data Of Ft819 Off-The-Shelf

Reuters
·
10 Dec 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 off-the-Shelf, Car T-Cell Product Candidate for Systemic Lupus Erythematosus

THOMSON REUTERS
·
10 Dec 2024

Fate Therapeutics Presents New Phase 1 Clinical Data of FT819 Off-the-shelf, CAR T-cell Product Candidate for Systemic Lupus Erythematosus

GlobeNewswire
·
10 Dec 2024

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Veeva Systems (VEEV) and Alcon (ALC)

TIPRANKS
·
06 Dec 2024

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
04 Dec 2024

Fate Therapeutics Announces Leadership Transition for 2025

TIPRANKS
·
30 Nov 2024

Fate Therapeutics Taps Bob Valamehr to Be CEO

Dow Jones
·
30 Nov 2024

BRIEF-Fate Therapeutics Says Bob Valamehr To Become President, CEO As Of Jan 2025

Reuters
·
30 Nov 2024

Fate Therapeutics CEO Wolchko to retire

TIPRANKS
·
30 Nov 2024

Fate Therapeutics Inc - Scott Wolchko to Continue as Strategic Advisor

THOMSON REUTERS
·
30 Nov 2024

Fate Therapeutics Inc - Bob Valamehr to Become President and CEO Jan 1, 2025

THOMSON REUTERS
·
30 Nov 2024

Fate Therapeutics Announces Leadership Transition

THOMSON REUTERS
·
30 Nov 2024